IP Verse

Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-Cyclodextrin

Patent No. EP3391890 (titled "Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-Cyclodextrin") was filed by Merck Sharp & Dohme on Jun 24, 2011. The application was issued on Aug 25, 2021.

Patent Summary

Stable intravenous formulation of posaconazole, an antifungal drug, for treating fungal infections. The formulation uses a modified cyclodextrin called Captisol and the chelating agent EDTA to solubilize and stabilize posaconazole in water. The cyclodextrin forms a complex with posaconazole to increase solubility, while EDTA helps maintain stability. The formulation can be diluted for infusion without precipitation, providing a practical and stable intravenous option for posaconazole administration.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ETHYPHARMMay 25, 2022LLR
FRESENIUS KABI DEUTSCHLANDMay 25, 2022FRESENIUS KABI DEUTSCHLAND
GENERICS UKMay 25, 2022ELKINGTON AND FIFE
AERAMay 25, 2022AERA

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3391890

MERCK SHARP & DOHME
Application Number
EP18171672A
Filing Date
Jun 24, 2011
Status
Granted And Under Opposition
Jul 23, 2021
Publication Date
Aug 25, 2021
External Links
Slate, Register , Google Patents